According to a press release, diabetes drug company Daiichi Sankyo Inc. today announced that the US FDA (Food and Drug Administration) have granted approval for diabetes drug Welchol. The type 2 diabetes drug is hailed as a unique pioneer drug that reduces both forms of cholesterol .
Welchol has been created following statistics that some 40 per cent of type 2 diabetics also suffer from high LDL cholesterol . Welchol plugs a gap in the market, apparently allowing patients to treat both health conditions at the same time.
Welchol has been through several phases of clinical trials, and its efficacy was highlighted during a presentation at the ADA (American Diabetes Association) Scientific Sessions in Chicago last year.
One diabetes expert, Ronald Goldberg MD, was reported as commenting: “Welchol now offers physicians a treatment option that addresses two major cardiovascular risk factors; elevated LDL cholesterol and blood glucose in patients with type 2 diabetes. Cardiovascular risk factors are of great concern because patients with type 2 diabetes have a significantly increased risk of developing cardiovascular disease . Once clinical cardiovascular disease develops, these patients have a poorer prognosis than normoglycemic patients.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…